Based on a cohort of 109 NSCLC patients who received ICI treatment (ICI cohort 1), this study found that patients with PTPRT mutations exhibited better ICI prognosis (Log-rank test, P = 0.011, Figure 6F). The gene discussed is PTPRT; the disease is non-small cell lung carcinoma.